Do you include pembrolizumab for metastatic/recurrent cervical cancer per KEYNOTE-826 regardless of PDL1 status?

PD-L1 expression is the biomarker currently approved for assessing potential responsiveness to immune checkpoint inhibitor (ICI) therapy in cervical and other malignancies. The search for better biomarkers is ongoing. With that caveat, KEYNOTE-826 was a randomized trial of chemotherapy +/- bevacizumab with pembrolizumab vs placebo. In their 2023 ASCO presentation, Monk and colleagues report statistically significantly improved progression-free and overall survival in the PD-L1 positive and all-c...